BPG is committed to discovery and dissemination of knowledge
Review
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Nov 10, 2015; 6(15): 1296-1308
Published online Nov 10, 2015. doi: 10.4239/wjd.v6.i15.1296
Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity
Chandra Kanti Chakraborti
Chandra Kanti Chakraborti, Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela 769015, Odisha, India
Author contributions: Chakraborti CK solely contributed to this manuscript.
Conflict-of-interest statement: The author has no conflict of interests.
Correspondence to: Dr. Chandra Kanti Chakraborti, Professor, Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela 769015, Odisha, India. chandrakanti_12@rediffmail.com
Telephone: +91-0977-6145092 Fax: +91-0661-2480752
Received: July 9, 2015
Peer-review started: July 14, 2015
First decision: August 25, 2015
Revised: September 14, 2015
Accepted: October 23, 2015
Article in press: October 27, 2015
Published online: November 10, 2015
Processing time: 124 Days and 15.4 Hours
Core Tip

Core tip: The objective of this article is to establish the connection of obesity with that of insulin resistance (IR) and type 2 diabetes mellitus (T2DM) by analyzing the recent developments in this field. The factors linking the three have been found to be some adipocytokines as well as certain other factors not of adipocyte origin. Of these, adiponectin appears to play the most beneficial role (so also leptin, peroxisome proliferator-activated receptors, apelin, etc.), while others (tumour necrosis factor-alpha, interleukin-6, resistin, retinol binding protein-4, dipeptidyl peptidase-4, plasminogen activator inhibitor-1, visfatin, free fatty acid, angiotensin II and toll-like receptors) are harmful. Agonists and antagonists of these factors may be designed to fight against obesity, thereby achieving protection for IR and T2DM.